Skip to main content
RIGL logo

RIGL · Rigel Pharmaceuticals Inc · Debt

Track RIGL — free
$41.27 +1.62 (+4.09%) Play latest call Q3 2026 earnings call transcript
Market Cap
$746.61M
Shares
18.83M
Volume · Nov 9 41.8K Avg daily vol (3M) 260.25K

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current operating lease liabilities 2026-09-30 USD 556,000 10-Q filed 2026-11-05
Loans payable, including current maturities 2026-09-30 USD 7,236,000 10-Q filed 2026-11-05
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current portion of loans payable
USD 7,236,000
Noncurrent loans payable
USD 0
Noncurrent operating lease liabilities 2026-09-30 USD 0 10-Q filed 2026-11-05
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1034842 CUSIP 766559702 13F (30d) 79 filings 60 filers Visit website Investor relations